trending Market Intelligence /marketintelligence/en/news-insights/trending/OJz7XBn_7gxvVfo7p-pf7A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers, Pfizer team with FitBit to track heart health in at-risk patients

Strong adoption of AI/ML monitoring tools is driven by tech leaders

Amazon e-commerce sales soar amid COVID-19

European Energy Insights - October 2020

Banking Essentials - October 2020

Bristol-Myers, Pfizer team with FitBit to track heart health in at-risk patients

Bristol-Myers Squibb Co. and Pfizer Inc. have teamed up with Fitbit Inc., maker of wearable fitness devices, to help detect arrhythmia in those at risk of stroke or heart failure.

Fitbit plans to apply for U.S. Food and Drug Administration clearance for software to detect atrial fibrillation, or AFib, on its devices but has not provided a timeline for the submission.

The company announced the partnership with the two makers of the blockbuster blood thinner Eliquis on Oct. 17 at the TIME 100 Health Summit as well as in a press release on the same day. Fitbit said the collaboration would help develop educational content and guidance for patients at risk of the heart condition, particularly those 65 and older. The condition can often be asymptomatic before a serious event.

AFib, the most common type of irregular heartbeat, is expected to affect about 8 million people in the U.S. in 2019, according to the Oct. 17 news release.

"Too many people discover that they are suffering from atrial fibrillation only after experiencing a stroke," said Joseph Eid, head of Medical Affairs at Bristol-Myers. "In fact, some studies suggest that this is true for more than 25% of people who have the condition."

By providing data on irregular heartbeats detected by Fitbit's wearable device, it is hoped that patients will discuss their heart condition with their physicians. "We are excited about wearables and how our work with Bristol-Myers and Fitbit may potentially help patients and physicians detect and understand heart rhythm irregularities," Pfizer Biopharmaceuticals Group President Angela Hwang said.

Bristol-Myers and Pfizer have emphasized real-world data — representing patients outside of the clinic — to track heart health and reach more patients at early stages of risk for a heart condition. Sales of the partners' drug Eliquis reached $3.76 billion in 2018.